MedDataX Logo

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

NCT ID: NCT05781113

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-01

Study Completion Date

2026-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS display clinically significant gait impairments. Initial gait lab "gold standard" data indicate that the Artificial Intelligence (AI)-based digital biomarker will prove to be highly effective at detecting changes in the MS patient's condition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple sclerosis (MS) is lifelong autoimmune disease that is typically first diagnosed in young adults; MS affects the central nervous system and can result in various impairments, including walking, cognition, dexterity, sleep, vision and bladder control. Notably, impairments to gait are the most common and are identified as the most impactful to a person with MS's (PwMS's) quality of life. Furthermore, ambulation is a key metric used to assess the severity of MS and is the basis for the Expanded Disability Status Scale (EDSS) that represents the global standard for assessing a patient's MS condition. For these reasons, clinicians employ a variety of gait tests to assess the severity and progression of the disease, which require frequent clinical visits and lack objective measurements as compared to what can be measured in a laboratory setting. Current scales do not detect subtle progression that could be indicative of early transformation into Secondary Progressive MS (SPMS) from Relapsing Remitting MS (RRMS) or significant progression in progressive forms of MS.

With advancements in wearable technologies and Artificial Intelligence (AI)-based algorithm development, clinicians can be provided with meaningful laboratory grade gait metrics collected in the patient's home environment to assist their practice. Objective walking information can be provided to clinicians to track the personalized progression of the disease to enable a more targeted treatment plan. A subset of this data is also shared with the patients via their smart phone app to keep them informed and motivated.

Several times per week, smart insoles in the patient's shoes will collect data from the embedded sensors (pressure sensors, accelerometer, gyroscope). The wearable smart insoles are fitted into a pair of the patient's "everyday use" shoes, and are very similar to the type of "comfort" insoles available from a local pharmacy. The smart insole data will be used to create AI-based personalized models that compute each individual's walking signature; this includes tracking of subtle changes over time (improvement, deterioration) as well as identifying specific gait phenotypes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must have a diagnosis of Multiple Sclerosis (MS) based on the McDonald criteria, within an age range of 18 to 60.
* The participant must have an Extended Disability Status Scale (EDSS) score at screening less than or equal to 6.5, inclusive.
* The participant cohort will include at least 3 participants at each site exhibiting one of the following gait phenotypes: ataxic, hemiplegic and spastic. (Some participants may exhibit more than one phenotype).
* The participant cohort will include at least 3 participants at each site with a progressive form of MS.

Exclusion Criteria

* Participants that are currently suffering from a musculoskeletal injury (e.g., sprain, fracture, strain, etc.) that limits their ability to use their full range of motion of any joint at the time of recruitment.
* Inability to provide informed consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Ottawa

OTHER

Sponsor Role collaborator

Barts & The London NHS Trust

OTHER

Sponsor Role collaborator

The Ottawa Hospital

OTHER

Sponsor Role collaborator

Brigham and Women's Hospital

OTHER

Sponsor Role collaborator

Celestra Health Systems

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gauruv Bose, Dr.

Role: PRINCIPAL_INVESTIGATOR

The Ottawa Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status ACTIVE_NOT_RECRUITING

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status COMPLETED

The Royal London Hospital

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bruce Ford

Role: CONTACT

Phone: 6132940620

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mays Jawad, Dr.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CelestraHealthmct1

Identifier Type: -

Identifier Source: org_study_id